Vemurafenib-induced toxic epidermal necrolysis: Is it an emerging side-effect of the drug?
Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, 34093, Çapa-Istanbul, Turkey.
S
S
Kılıç
Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, 34093, Çapa-Istanbul, Turkey.
E
E
Özkaya
Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, 34093, Çapa-Istanbul, Turkey.
C
C
Baykal
Department of Medical Oncology, Institute of Oncology, Istanbul University, 34093, Çapa-Istanbul, Turkey.
S
S
Vatansever
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D000077484:Vemurafenib / Q000009:adverse effects*
D000970:Antineoplastic Agents; D000077484:Vemurafenib